Literature DB >> 31704271

Differences in mechanisms underlying reinstatement of cigarette smoke extract- and nicotine-seeking behavior in rats.

Sarah J Cross1, Daisy D Reynaga2, Michelle Cano2, James D Belluzzi2, Nurulain T Zaveri3, Frances M Leslie4.   

Abstract

Despite extensive research, current therapies for smoking cessation are largely ineffective at maintaining abstinence for more than a year. Whereas most preclinical studies use nicotine alone, the goal of the present study was to evaluate whether inclusion of non-nicotine tobacco constituents provides better face validity for the development of new pharmacological therapies for smoking cessation. Here, we trained adult male rats to self-administer nicotine alone or cigarette smoke extract (CSE), which contains nicotine and other aqueous constituents of cigarette smoke. After stable self-administration behavior was established, animals underwent extinction training followed by drug and cue primed reinstatement testing. We show that animals that self-administered CSE had significant reinstatement in all drug and drug + cue stimulus conditions whereas animals that self-administered nicotine only showed significant reinstatement in the drug + cue conditions. AT-1001, an α3β4 nicotinic acetylcholine receptor (nAChR) functional antagonist, attenuated drug + cue-primed reinstatement of both CSE- and nicotine-seeking behavior. However, AT-1001 was less potent in blocking drug-primed reinstatement in animals that had self-administered CSE than in those that had self-administered nicotine alone. This was the case even when nicotine was used to prime reinstatement in animals that had self-administered CSE, suggesting that prior CSE exposure had altered the functional role of α3β4-containing nAChRs in drug-seeking behavior. These findings confirm the importance of non-nicotine tobacco constituents and α3β4* nAChRs in cue- and nicotine-primed craving. They also suggest that tests using CSE may be more valid models to study tobacco dependence than use of nicotine alone.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cigarette smoke constituents; Cue reinstatement; Drug-primed reinstatement; Nicotine; Tobacco; α3β4 nicotinic acetylcholine receptors

Mesh:

Substances:

Year:  2019        PMID: 31704271      PMCID: PMC7034132          DOI: 10.1016/j.neuropharm.2019.107846

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  47 in total

1.  Measuring nicotinic receptors with characteristics of alpha4beta2, alpha3beta2 and alpha3beta4 subtypes in rat tissues by autoradiography.

Authors:  David C Perry; Yingxian Xiao; Henry N Nguyen; John L Musachio; Martha I Dávila-García; Kenneth J Kellar
Journal:  J Neurochem       Date:  2002-08       Impact factor: 5.372

2.  Craving is associated with smoking relapse: findings from three prospective studies.

Authors:  J D Killen; S P Fortmann
Journal:  Exp Clin Psychopharmacol       Date:  1997-05       Impact factor: 3.157

Review 3.  Role of cues and contexts on drug-seeking behaviour.

Authors:  Christina J Perry; Isabel Zbukvic; Jee Hyun Kim; Andrew J Lawrence
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

4.  Effects of varenicline and mecamylamine on the acquisition, expression, and reinstatement of nicotine-conditioned place preference by drug priming in rats.

Authors:  Grazyna Biala; Natasza Staniak; Barbara Budzynska
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-03-10       Impact factor: 3.000

5.  Reinforcing and neural activating effects of norharmane, a non-nicotine tobacco constituent, alone and in combination with nicotine.

Authors:  Monica M Arnold; Sandra E Loughlin; James D Belluzzi; Frances M Leslie
Journal:  Neuropharmacology       Date:  2014-06-05       Impact factor: 5.250

6.  Decreased signs of nicotine withdrawal in mice null for the beta4 nicotinic acetylcholine receptor subunit.

Authors:  Ramiro Salas; Fredalina Pieri; Mariella De Biasi
Journal:  J Neurosci       Date:  2004-11-10       Impact factor: 6.167

7.  The alpha4beta2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats.

Authors:  Eoin C O'Connor; Dale Parker; Hans Rollema; Andy N Mead
Journal:  Psychopharmacology (Berl)       Date:  2009-12-05       Impact factor: 4.530

Review 8.  Neurocircuitry of addiction.

Authors:  George F Koob; Nora D Volkow
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

9.  The addition of five minor tobacco alkaloids increases nicotine-induced hyperactivity, sensitization and intravenous self-administration in rats.

Authors:  Kelly J Clemens; Stephanie Caillé; Luis Stinus; Martine Cador
Journal:  Int J Neuropsychopharmacol       Date:  2009-04-15       Impact factor: 5.176

10.  Habenular α5 nicotinic receptor subunit signalling controls nicotine intake.

Authors:  Christie D Fowler; Qun Lu; Paul M Johnson; Michael J Marks; Paul J Kenny
Journal:  Nature       Date:  2011-01-30       Impact factor: 49.962

View more
  4 in total

1.  Cigarette Smoke Extract, but Not Electronic Cigarette Aerosol Extract, Inhibits Monoamine Oxidase in vitro and Produces Greater Acute Aversive/Anhedonic Effects Than Nicotine Alone on Intracranial Self-Stimulation in Rats.

Authors:  Andrew C Harris; Peter Muelken; Aleksandra Alcheva; Irina Stepanov; Mark G LeSage
Journal:  Front Neurosci       Date:  2022-05-25       Impact factor: 5.152

Review 2.  Unique, long-term effects of nicotine on adolescent brain.

Authors:  Frances M Leslie
Journal:  Pharmacol Biochem Behav       Date:  2020-07-30       Impact factor: 3.533

3.  Chronic exposure to cigarette smoke extract upregulates nicotinic receptor binding in adult and adolescent rats.

Authors:  Michelle Cano; Daisy D Reynaga; James D Belluzzi; Sandra E Loughlin; Frances Leslie
Journal:  Neuropharmacology       Date:  2020-09-17       Impact factor: 5.250

Review 4.  Monoamine oxidase inhibition in cigarette smokers: From preclinical studies to tobacco product regulation.

Authors:  Alan F Sved; Jillian J Weeks; Anthony A Grace; Tracy T Smith; Eric C Donny
Journal:  Front Neurosci       Date:  2022-08-16       Impact factor: 5.152

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.